Immediately Positions Gilead as a Leader in Cell Therapy Kite’s Lead CAR T Therapy Candidate, Axicabtagene Ciloleucel, Under Priority Review in the U.S. and Expedited Review in the EU Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation Leverages Gilead’s Expertise in Rapidly Advancing Therapies to Address Unmet Patient
RESTON, VA (Aug. 14, 2017) – Leidos (LDOS) (NYSE: LDOS), a FORTUNE 500 science and technology company, has signed a Memorandum of Understanding (MOU) with Biosortia Pharmaceuticals to explore creating a new business relationship with a focus on identifying and advancing immuno-oncology and other immunotherapeutic opportunities.
